EQS-Adhoc: Subsidiaries of Vita 34 reach agreement with US licensor
|
EQS-Ad-hoc: Vita 34 AG / Key word(s): Agreement/Scheme of Arrangement Subsidiaries of Vita 34 reach agreement with US licensor The civil action was filed on 27 September 2023 in a United States district court. The complaint alleged claims, among others, for material breach of the agreement by the Licensor. Despite the filing of the action, the parties involved continued negotiations in good faith to resolve this dispute. Today the parties completed their negotiations for a termination agreement of the original license agreement and a new know-how license agreement between FamiCordTx and PBKM on the one hand and the Licensor on the other, which solves the topic of the lawsuit. The new know-how licensing agreement is limited in its scope and covers technology and know-how previously transferred by the Licensor to FamiCordTx and PBKM. The know-how licensing agreement secures access to the CAR-T technology required in particular for the modified projects and provides for lower-level market standard royalty payments by FamiCordTx and PBKM in case of commercial use or sale without milestone payments.
--- End of inside information pursuant to Art. 17 MAR --- End of Inside Information Information and Explanation of the Issuer to this announcement: Contact:
Company Profile Vita 34 was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. Due to the expansion of the business model following the merger with PBKM, the company intends to invest in the areas of Cell & Gene therapies and CDMO. The body's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with around one million units of stored biological material at Vita 34.
09-Aug-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Vita 34 AG |
| Deutscher Platz 5a | |
| 04103 Leipzig | |
| Germany | |
| Phone: | +49(0341)48792-40 |
| Fax: | +49(0341)48792-39 |
| E-mail: | ir@vita34.de |
| Internet: | www.vita34.de |
| ISIN: | DE000A0BL849 |
| WKN: | A0BL84 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1965227 |
| End of Announcement | EQS News Service |
|
|
1965227 09-Aug-2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 20,41 | 19,93 | 20,07 | 28,42 | 68,94 | 77,06 | 86,00 | |
| EBITDA1,2 | 4,72 | 5,43 | 5,34 | 0,81 | -3,56 | 5,57 | 7,40 | |
| EBITDA-Margin3 | 23,13 | 27,25 | 26,61 | 2,85 | -5,16 | 7,23 | 8,61 | |
| EBIT1,4 | 2,63 | 2,45 | 2,38 | -3,07 | -27,28 | -3,12 | -1,20 | |
| EBIT-Margin5 | 12,89 | 12,29 | 11,86 | -10,80 | -39,57 | -4,05 | -1,40 | |
| Net Profit (Loss)1 | 0,83 | 0,72 | 1,50 | -3,93 | -27,38 | -2,03 | -2,90 | |
| Net-Margin6 | 4,07 | 3,61 | 7,47 | -13,83 | -39,72 | -2,63 | -3,37 | |
| Cashflow1,7 | 4,60 | 6,32 | 3,98 | 2,73 | -4,49 | 9,15 | 0,00 | |
| Earnings per share8 | 0,20 | 0,18 | 0,37 | -0,63 | -1,71 | -0,12 | -0,16 | |
| Dividend per share8 | 0,16 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Vita 34 | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0BL84 | DE000A0BL849 | AG | 72,68 Mio € | 27.03.2007 | Halten | 9F3J899W+W5 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 0,00 | 27,07 | 0,00 | -35,83 | 3,19 | 7,94 | 0,94 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 28.06.2024 | 31.05.2024 | 30.08.2024 | 22.11.2024 | 30.04.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -4,19% | -8,57% | -21,37% | -19,22% | -72,53% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
